Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q1 2026 Earnings Presentation
16 slides from Q-linea Ab's earnings presentation, Apr 30, 2026
Slide 1: 2026 Q1 Report
Sustainable healthcare for a new generation 2026 Q1 Report April 30th, 2026
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Topics for today
❖ Commercial progress update ❖ FDA clearance for expanded US panel Topics for ❖ Priorities for 2026 today ❖ Financial update ❖ Respond to your questions
Slide 4: Key messages for today
Key messages for today Q1 2026 was a record quarter with shipment of seven ASTar 1 instruments and our highest demand for consumables FDA clearance of our expanded US menu clearly differentiates 2 ASTar and meets key physician requirements for rapid AST US market expected to jump-start from Q2 2026
Slide 5: Q-linea revolutionising AST
Q-linea revolutionising AST | Flagship ASTar platform designed to save lives Fully-automated, random 1st access platform Minutes hands-on time ~2 simple interface, load-and-go system ➢ Comprehensive menu ➢ High reproducibility ➢ High throughput with 12 Hours turn-around time samples in parallel ~6 s
Slide 6: A new standard of care
A new standard of care | Critical patient testing moving to rapid AST Clinical value Current standard of care Emerging new standard of care of information Colony-based AST Positive Blood Culture AST Whole Blood AST ❖ 5 – 7m blood infection tests Clinically- ❖ 5 – 10m critical non-blood AST urgent te
Slide 7: Pipeline progression
Pipeline progression | Evaluation activity accelerating driven by US market In Evaluation and/or Contracted ASTars ASTars in Clinical Use ASTar tests (MSEK) Contracting process1 89 4,6 Evaluation New since Q4 2025 16 83 242 4,1 14 Contracting 19 12 56 17 3,0 38 12 1,8 31 5 1,3 7 4 4 2 N/A2 N/A2 >80
Slide 8: FDA clearance
FDA clearance | Expanded ASTar panel now available in US What is different … ❖ + 93 new drug-bug combinations added (now 215 in total) ❖ Clinically important drugs now available, e.g., Cefriaxone, Ertapenem, others ❖ Panel updated with all the latest FDA breakpoints What does this mean for customers
Slide 9: US panel
US panel | Now clearly differentiated in the market for clinical utility ASTar BC G- FDA v2 menu versus ‘next best alternative’ ❖ ASTar now with c. 2x the drug-bug combinations ❖ 9 drugs not available at all on the next-best on-market alternative ❖ 1 pathogen (M. morganii) not available on next-best
Slide 10: Voice-of-customer
Voice-of-customer | Actionable diagnostic results at Baylor, Scott & White Publication describing ASTar impact in real-world setting with the team at BS&W, Texas (USA) ❖ Pioneering work with rapid AST by the team at Baylor, Scott & White was recognised in Microbiology Spectrum in April 2026 ❖ Confir
Slide 11: Coming soon
Coming soon | Planned launch of dedicated Isolate (non-blood) kit ❖ Two posters by ASTar customers presented at ESCMID (Munich, April 2026) demonstrating: ❖ Performance of ASTar for isolates equal-or-better than positive blood culture results ❖ Establish criteria and workflow that other labs can use
Slide 12: Short-term priorities
Short-term priorities | Accelerate pipeline conversion Commercial ❖ Conversion drive for all US customers awaiting ‘v2 menu’ priorities ❖ Support Italian customers to increase testing rate (% of PBCs) ❖ Expand geographic footprint capitalising on high interest for ASTar globally (new distribution ma
Slide 13: Financial highlights
Financial highlights | Q1 2026 REVENUES ❖ Net sales in the quarter of SEK 2.0 million, lower than same period last year due to lower capital sales of ASTar in the quarter ❖ Consumables (recurring income) still on a low level but 60 percent higher than the same quarter 2025 (SEK 1.4 vs 0.9 million).
Slide 14: OPEX development
OPEX development | Reducing operating costs through Q1 2023 – Q1 2026 ❖ EBIT improvement during the past three years has primarily come from lower operating expenses Personnel expenses + Other external costs (SEK thousand) ❖ EBIT improvement the next coming three years will 25 000 primarily come fro
Slide 15: Key topics for Q-linea going forward financially
Key topics for Q-linea going forward financially Increase consumables sales ❖ Consumables sales is recurring by nature and the main buidling block of our business model ❖ Sell and install new ASTar; shortening sales cycles will be a key ❖ Increase share of new contracts in the US market → high(er) p
Slide 16: Thank you!
Thank Questions? you!